Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OBI-992 |
Synonyms | |
Therapy Description |
OBI-992 is an antibody-drug conjugate (ADC) comprising an antibody that targets TACSTD2 (TROP2) linked to a topoisomerase I inhibitor, which may induce cytotoxicity against TROP2-expressing tumor cells and inhibit tumor growth (Cancer Res (2024) 84 (6_Supplement): 1893). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OBI-992 | OBI992|OBI 992|BSI 992|BSI-992|BSI992 | TROP2 Antibody 13 | OBI-992 is an antibody-drug conjugate (ADC) comprising an antibody that targets TACSTD2 (TROP2) linked to a topoisomerase I inhibitor, which may induce cytotoxicity against TROP2-expressing tumor cells and inhibit tumor growth (Cancer Res (2024) 84 (6_Supplement): 1893). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06480240 | Phase Ib/II | OBI-992 | A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |